Stockreport

FDA Moves Ulixacaltamide Forward As Praxis Valuation Gap Draws Focus [Yahoo! Finance]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF The U.S. FDA has accepted Praxis Precision Medicines' New Drug Application for ulixacaltamide to treat essential tremor. The agency has also granted ulixacaltamide Br [Read more]